Polen Capital Management LLC Has $3.93 Million Stock Holdings in Repligen Corporation (NASDAQ:RGEN)

Key Points

• Polen Capital Management LLC has reduced its stake in Repligen Corporation by 23.8%, owning 30,902 shares after selling 9,654 shares during the first quarter.
• Research analysts have set varying price targets for Repligen, with JPMorgan Chase lowering their target to $190.00 while Royal Bank Of Canada raised theirs to $204.00, indicating a consensus average price target of $169.45.
• Repligen reported $182.37 million in revenue for the latest quarter, exceeding analysts' expectations, despite missing their earnings per share estimate by 3 cents.

Polen Capital Management LLC decreased its position in shares of Repligen Corporation (NASDAQ:RGEN - Free Report) by 23.8% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 30,902 shares of the biotechnology company's stock after selling 9,654 shares during the period. Polen Capital Management LLC owned about 0.06% of Repligen worth $3,932,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Raiffeisen Bank International AG bought a new position in Repligen in the 4th quarter worth approximately $29,000. Itau Unibanco Holding S.A. acquired a new stake in Repligen in the 4th quarter valued at approximately $40,000. Signaturefd LLC increased its position in Repligen by 65.3% in the 1st quarter. Signaturefd LLC now owns 324 shares of the biotechnology company's stock valued at $41,000 after acquiring an additional 128 shares during the period. Center for Financial Planning Inc. increased its position in Repligen by 110.3% in the 1st quarter. Center for Financial Planning Inc. now owns 368 shares of the biotechnology company's stock valued at $47,000 after acquiring an additional 193 shares during the period. Finally, UMB Bank n.a. increased its position in Repligen by 99.4% in the 1st quarter. UMB Bank n.a. now owns 666 shares of the biotechnology company's stock valued at $85,000 after acquiring an additional 332 shares during the period. Hedge funds and other institutional investors own 97.64% of the company's stock.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the stock. JPMorgan Chase & Co. reduced their price target on shares of Repligen from $200.00 to $190.00 and set an "overweight" rating for the company in a research note on Tuesday, April 29th. Canaccord Genuity Group reduced their price target on shares of Repligen from $170.00 to $150.00 and set a "hold" rating for the company in a research note on Wednesday, April 16th. Evercore ISI reduced their price target on shares of Repligen from $140.00 to $130.00 and set an "in-line" rating for the company in a research note on Tuesday, July 8th. Wall Street Zen lowered shares of Repligen from a "buy" rating to a "hold" rating in a research note on Sunday, June 29th. Finally, Royal Bank Of Canada upped their price target on shares of Repligen from $193.00 to $204.00 and gave the stock an "outperform" rating in a research note on Wednesday, July 30th. Four equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $169.45.

Repligen Trading Up 8.5%

Shares of RGEN stock traded up $9.52 during trading hours on Tuesday, reaching $121.40. 969,803 shares of the stock traded hands, compared to its average volume of 1,028,236. Repligen Corporation has a 1-year low of $102.96 and a 1-year high of $182.52. The business has a fifty day moving average price of $122.57 and a 200 day moving average price of $133.66. The company has a quick ratio of 7.32, a current ratio of 8.59 and a debt-to-equity ratio of 0.26. The firm has a market capitalization of $6.83 billion, a PE ratio of -485.58, a PEG ratio of 2.06 and a beta of 1.05.

Repligen (NASDAQ:RGEN - Get Free Report) last released its quarterly earnings results on Tuesday, July 29th. The biotechnology company reported $0.37 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.40 by ($0.03). Repligen had a negative net margin of 2.05% and a positive return on equity of 4.61%. The firm had revenue of $182.37 million for the quarter, compared to analyst estimates of $174.62 million. During the same quarter in the prior year, the firm earned $0.40 EPS. The firm's revenue was up 14.8% compared to the same quarter last year. On average, equities research analysts forecast that Repligen Corporation will post 1.72 EPS for the current year.

Insider Activity

In other news, Director Martin D. Madaus purchased 1,800 shares of the business's stock in a transaction dated Friday, August 8th. The shares were acquired at an average price of $112.13 per share, for a total transaction of $201,834.00. Following the completion of the acquisition, the director directly owned 1,800 shares of the company's stock, valued at $201,834. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 1.20% of the stock is owned by corporate insiders.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.